初期CKDにおける利尿薬と体液量過多 (DOCK)
CKDにおける利尿薬と細胞外容積の変化、ナトリウム利尿ペプチド、症状、心血管転帰との関連
Almost 15% of Americans have chronic kidney disease (CKD), with an even higher rate in Veterans due to common risk factors such as high blood pressure and diabetes. People with CKD have a high risk of cardiovascular (CV) diseases, such as heart attacks, heart failure, and strokes. Extra fluid in the body, called volume overload, may lead to CV disease in people with CKD. It is unknown if volume overload develops in the earliest stages of CKD, when treating it with common, inexpensive medicines called diuretics may improve long-term CV outcomes. This study will lay important groundwork to answer this question in Veterans with early CKD by comparing two ways to measure volume overload and studying the change in common symptoms like fatigue and short-term CV function after treatment with diuretic medicines.
調査の概要
状態
詳細な説明
The investigators previously showed that brain natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP), measures of ventricular stretch, are associated with death and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) stages 1-3, and the investigators' preliminary pilot results suggest that these natriuretic peptides may correlate with objective measures of excess extracellular volume (ECV) and with symptoms common in CKD. The overarching objective is to determine if initiation of diuretic treatment or increase in dose is associated with changes in BNP and NT-pro-BNP, patient-reported symptom burden, and short-term hemodynamic parameters in patients with CKD stages 1-3 and elevated blood pressure, and whether these changes correlate with changes in ECV. The central hypothesis is that the change in ECV after starting or increasing diuretics in Veterans with stages 1-3 CKD is associated with changes in 1) natriuretic peptides, 2) patient-level factors, and 3) CV physiology.
The investigators will compare the changes in natriuretic peptides, symptoms, and CV parameters with the change in ECV after diuretic initiation or dose increase. The primary aim is to determine if initiation of diuretic treatment or increase in diuretic dose is associated with changes in natriuretic peptides. Secondary aims are to determine the effect of diuretic change on patient-reported symptom burden, and CV physiology.
This clinical trial will include 46 outpatients with CKD stages 1-3 and blood pressure >140/90 mmHg. At the first visit, the investigators will initiate or increase the dose of a thiazide or loop diuretic. Study measures other than echocardiogram will be repeated 4 weeks after the intervention to determine changes in these parameters. ECV will be measured by whole-body multifrequency bioimpedance spectroscopy (BIS), which is a validated, non-invasive, painless measure of ECV. Plasma BNP and NT-pro-BNP will be measured, and patient-reported fatigue, depression, and quality of life will be quantified using validated questionnaires. Hemodynamic parameters include blood pressure, pulse pressure, and total peripheral resistance index (TPRI) and cardiac index measured by Non-Invasive Hemodynamic Monitoring. A transthoracic echocardiogram will measure left ventricular mass index, valvular disease, and diastolic dysfunction.
Variables will be compared within participants between baseline and Visit 2 using paired Wilcoxon Signed Rank tests or paired Student's t tests, depending on variable distributions. Correlations between change in ECV/total body weight and all continuous outcome measures will be analyzed using Spearman or Pearson correlations, applying appropriate transformations. Linear regression analysis will control for clinically relevant variables. The relationship between ECV/total body weight and natriuretic peptides from both visits will be evaluated using a mixed effects model to account for the change in these measures between baseline and Visit 2.
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030-4211
- Michael E. DeBakey VA Medical Center, Houston, TX
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Male or female Veterans age 18 years or older. There will be no upper age limit.
-
The presence of CKD stages 1, 2, or 3, as defined below by Kidney Disease Improving Global Outcomes guidelines, for a period of at least 3 months.
- Stage 1: eGFR 90 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
- Stage 2: eGFR 60-89 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
- Stage 3: eGFR 30-59 mL/min/1.73 m2.
-
Measured blood pressure either >140 mmHg systolic or >90 mmHg diastolic at the two most recent clinic visits.
-
Able to understand and sign informed consent after the nature of the study has been fully explained.
Exclusion Criteria:
- Unable to understand or provide informed consent.
- Unwilling or unable to participate in the protocol or comply with any of its components.
- CKD stages 4-5, defined as eGFR <30 mL/min/1.73 m2.
- Receiving chronic hemodialysis or peritoneal dialysis.
- Recipient of a kidney transplant.
- Serum potassium <3.5 mEq/L at baseline.
- Known left ventricular ejection fraction <40% on visual estimate based on chart review of available echocardiogram data.
- Known hepatic cirrhosis.
- Major limb amputation.
- Known pregnancy.
- Presence of a pacemaker or defibrillator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Diuretic augmentation
The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed. |
The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in NT-pro-BNP
時間枠:4 weeks
|
Change in NT-pro-BNP from baseline to 4 weeks after intervention |
4 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in BNP
時間枠:4 weeks
|
Change in BNP from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in FACIT-F score
時間枠:4 weeks
|
Change in fatigue as measured by FACIT-F score from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in QIDS-SR16
時間枠:4 weeks
|
Change in depression as measured by the QIDS-SR16 from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in KDQOL
時間枠:4 weeks
|
Change in quality of life as measured by the KDQOL from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in total peripheral resistance index
時間枠:4 weeks
|
Change in total peripheral resistance index from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in systolic blood pressure
時間枠:4 weeks
|
Change in systolic blood pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in diastolic blood pressure
時間枠:4 weeks
|
Change in diastolic blood pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in mean arterial pressure
時間枠:4 weeks
|
Change in mean arterial pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in pulse pressure
時間枠:4 weeks
|
Change in pulse pressure from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in cardiac index
時間枠:4 weeks
|
Change in cardiac index from baseline to 4 weeks after intervention |
4 weeks
|
|
Change in extracellular volume normalized/total body weight
時間枠:4 weeks
|
Change in extracellular volume normalized to total body weight from baseline to 4 weeks after intervention |
4 weeks
|
協力者と研究者
捜査官
- 主任研究者:Lucile P Gregg, MD MS、Michael E. DeBakey VA Medical Center, Houston, TX
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 血管疾患
- 心血管疾患
- 病理学的プロセス
- 男性の泌尿生殖器疾患
- 腎臓病
- 泌尿器疾患
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 慢性疾患
- 疾患の属性
- 腎不全
- 病理学的状態、徴候および症状
- 高血圧症
- 腎不全、慢性
- 硫黄化合物
- 有機化学物質
- ピリジン
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- 炭化水素、周期的
- カルボン酸
- 炭化水素、芳香
- アミド
- アニリン化合物
- アミン
- ベンゼン誘導体
- フタリミド
- 酸、炭素環
- イソインドール
- ベンゼンスルホンアミド
- スルホンアミド
- スルファニラミド
- スルホン
- アミノベンゾエート
- ベンゾエート
- ケトン
- ベンゾフェノン
- クロロチアジド
- ベンゾチアジアジン
- チアジド
- Imides
- メタアミノベンゾ酸塩
- トルセミド
- フロセミド
- ブメタニド
- ヒドロクロロチアジド
- クロルタリドン
その他の研究ID番号
- NEPH-001-21S
- 1IK2CX002368-01A1 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。